4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline | 379230-84-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline
• 英文别名: N-(2,4-dichloro-5-methoxyphenyl)-5-(oxan-4-yloxy)-7-(2-piperidin-1-ylethoxy)quinazolin-4-amine
• CAS: 379230-84-9
• 化学式: C₂₇H₃₂Cl₂N₄O₄
• 分子量: 547.481
• InChiKey: VSCFUBQXHXHWBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  78
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Quinazoline derivatives for treatment of tumours
  申请人：——

  公开号：US20040214841A1

  公开（公告）日：2004-10-28

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease. 1

  本发明涉及公式（I）的喹嗪衍生物，其中Q1、Z、m、R1、R2、R3和Q2中的每个都具有描述中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用于抗侵袭剂以限制和/或治疗实体肿瘤疾病的药物中的使用。
• Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine
  申请人：Barge Alan

  公开号：US20060142297A1

  公开（公告）日：2006-06-29

  The invention concerns a combination comprising an inhibitor of Src kinase and the cytotoxic agent gemcitabine, a pharmaceutical composition comprising such a combination and its use in the treatment or prophylaxis of cancer, particularly of pancreatic cancer.

  本发明涉及一种组合物，包括Src激酶抑制剂和细胞毒素吉西他滨，一种含有该组合物的药物组合物以及其在治疗或预防癌症，特别是胰腺癌方面的用途。
• Quinazoline derivatives for the treatment of t cell mediated diseases
  申请人：Moore Corine Nelly

  公开号：US20050038050A1

  公开（公告）日：2005-02-17

  The invention concerns the use of the quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

  本发明涉及在温血动物中预防或治疗T细胞介导的疾病或医疗状况的药物制剂的制造中使用公式（I）的喹唑啉衍生物，其中Q1，Z，m，R1，R2，R3和Q2中的每一个都具有描述中定义的任何含义。
• Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
  申请人：Curwen Owen Jon

  公开号：US20060223815A1

  公开（公告）日：2006-10-05

  The invention relates to the use of an anti-angiogenic agent in combination with an inhibitor of the Src family of non-receptor tyrosine kinases in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis, the Src kinase inhibitor being administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent.

  本发明涉及在制造一种药物时使用抗血管生成剂与Src家族非受体酪氨酸激酶抑制剂相结合，用于治疗与血管生成有关的疾病状态，如在温血哺乳动物（如人类）中进行实质性正常血压治疗。 Src激酶抑制剂的用量有效地对抗抗血管生成剂引起的高血压。
• Quinazoline derivatives for the treatment of tumours
  申请人：Hennequin Francois Andre Laurent

  公开号：US20060258642A1

  公开（公告）日：2006-11-16

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  本发明涉及公式（I）的喹唑啉衍生物，其中Q1，Z，m，R1，R2，R3和Q2中的每一个都具有描述中定义的任何含义；其制备过程，含有它们的制药组合物以及它们在制造用于抗侵袭剂在包含和/或治疗实体肿瘤疾病的药物中的应用。